Results 271 to 280 of about 121,067 (308)

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.

, 2020
6017Background: Vigil is an autologous tumor cell vaccine constructed from autologous harvested tumor tissue transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin thereby creating TGFβ e...
R. Rocconi, J. Chan, M. Barve, D. Tewari, J. Bottsford-Miller, M. Tang, P. Aaron, G. Wallraven, E. Bognar, L. Manning, J. Nemunaitis, D. Shanahan, B. Slomovitz, T. Herzog, B. Monk, R. Coleman   +15 more
semanticscholar   +1 more source

Connecting social media use with gaps in knowledge and participation in a protest context: the case of candle light vigil in South Korea

Asian Journal of Communication, 2018
This study sheds light on the recent use of social media for protests, with the 2016 South Korean candle light vigils as the case study. An extensive amount of literature has explored social media’s potential for informing and mobilizing the public to ...
Sangwon Lee
semanticscholar   +1 more source

Pharmacovigilance is … Vigilance

Drug Safety, 2015
The world changes continuously and pharmacovigilance as a new discipline also must change. There are new fields opening with novel challenges whilst we are still perfecting ways to manage and improve the basic challenges such as inadequate data for decision making and under-reporting.
Rachida Soulayamani Bencheikh, I. Ralph Edwards   +1 more
openaire   +3 more sources

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

Journal of pediatric hematology/oncology, 2017
Ewing sarcoma is a highly resistant disease with a
Maurizio Ghisoli, M. Rutledge, P. Stephens, R. Mennel, M. Barve, Meghan Manley, B. R. Oliai, K. Murphy, L. Manning, B. Gutierrez, Priyanka Rangadass, A. Walker, Zhaohui Wang, D. Rao, Ned Adams, G. Wallraven, N. Senzer, J. Nemunaitis   +17 more
semanticscholar   +1 more source

On the Nature of Vigilance

Human Factors: The Journal of the Human Factors and Ergonomics Society, 2017
Objective: I explore the origins, theoretical underpinnings, applications, and importance of vigilance in a world ever more dominated by semiautomated, automated, and autonomous machines. Background: The empirical genesis of vigilance is taken as a case study in the etiology of the application of the behavioral sciences to the human culture of ...
openaire   +4 more sources

Keeping Vigil: The Emergence of Vigilance Committees in Pre-Civil War America

Perspectives on Politics, 2018
What explains the emergence of organized private enforcement in the United States? We study the formation of vigilance committees—that is, coercive groups organized in a manner not officially sanctioned by state law and with the purpose of establishing ...
J. Obert, Eleonora Mattiacci
semanticscholar   +1 more source

The Lucid Vigil

, 2019
Misunderstandings, misreadings, and dismissals of deconstruction and, more generally, the work of Jacques Derrida have been persistent both within and outside academic circles.
Stella Gaon
semanticscholar   +1 more source

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Cancer Gene Therapy, 2021
R. Rocconi, E. E. Stevens, J. Bottsford-Miller, S. Ghamande, J. Elder, L. Demars, A. Munkarah, P. Aaron, L. Stanbery, G. Wallraven, E. Bognar, Meghan Manley, S. Horvath, L. Manning, Adam Walter, E. Galanis, T. Herzog, B. Monk, R. Coleman, J. Nemunaitis   +19 more
semanticscholar   +1 more source

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

Gynecologic Oncology, 2021
R. Rocconi, B. Monk, Adam Walter, T. Herzog, E. Galanis, L. Manning, E. Bognar, G. Wallraven, L. Stanbery, P. Aaron, N. Senzer, R. Coleman, J. Nemunaitis   +12 more
semanticscholar   +1 more source

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.

The Lancet Oncology, 2020
R. Rocconi, E. Grosen, S. Ghamande, J. Chan, M. Barve, Jonathan C. Oh, D. Tewari, P. Morris, E. E. Stevens, J. Bottsford-Miller, M. Tang, P. Aaron, L. Stanbery, S. Horvath, G. Wallraven, E. Bognar, L. Manning, J. Nemunaitis, D. Shanahan, B. Slomovitz, T. Herzog, B. Monk, R. Coleman   +22 more
semanticscholar   +1 more source